Ratings Daewoong Co., Ltd.

Equities

A003090

KR7003090008

End-of-day quote Korea S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
18,640 ^KRW	-2.15%		-3.27%	-9.73%

24/04	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT
08/03	Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 404.97 for the 2024 fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DAEWOONG CO., LTD.	-9.73%	560M		-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+22.65%	44.12B		B-
OTSUKA HOLDINGS CO., LTD.	+22.22%	22.61B		B+
SANDOZ GROUP AG	+18.00%	15.11B		-
CIPLA LIMITED	+15.62%	13.61B		B+
ZYDUS LIFESCIENCES LIMITED	+59.58%	13.34B		B
ONO PHARMACEUTICAL CO., LTD.	-8.98%	6.94B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+15.65%	5.75B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes